發(fā)布時(shí)間：2018-01-30 12:42

  本文關(guān)鍵詞： 阿侖膦酸鈉片 阿法骨化醇膠囊 圍絕經(jīng)期骨質(zhì)疏松 安全性　出處：《中國(guó)臨床藥理學(xué)雜志》2017年06期 　論文類(lèi)型：期刊論文

【摘要】：目的觀察阿侖膦酸鈉片聯(lián)合阿法骨化醇膠囊治療圍絕經(jīng)期骨質(zhì)疏松的臨床療效及安全性。方法將56例圍絕經(jīng)期骨質(zhì)疏松患者隨機(jī)分為對(duì)照組28例和試驗(yàn)組28例。對(duì)照組阿法骨化醇每次0.25μg,qd,口服;試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上,予以阿侖膦酸鈉每次70 mg,qd,口服。比較2組患者的臨床療效、血清水通道蛋白1(AQP1)、基質(zhì)金屬蛋白酶2(MMP-2)、骨堿性磷酸酶(BALP)、Ⅰ型膠原C端肽(CTX-Ⅰ)水平及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對(duì)照組的總有效率分別為92.86%(26/28例)和71.43%(20/28例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組和對(duì)照組的AQP1分別為(23.53±3.02),(30.65±4.31)μg·L~(-1);MMP-2分別為(60.37±8.35),(66.45±8.47)μg·L~(-1);BALP分別為(20.04±2.57),(24.38±3.32)μg·L~(-1);CTX-I分別為(0.75±0.06),(0.83±0.09)ng·L~(-1),差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。試驗(yàn)組發(fā)生的藥物不良反應(yīng)主要有腹瀉和惡心,對(duì)照組發(fā)生的藥物不良反應(yīng)主要有便秘和惡心。2組患者的藥物不良反應(yīng)發(fā)生率均為7.14%,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論阿侖膦酸鈉片聯(lián)合阿法骨化醇膠囊治療圍絕經(jīng)期骨質(zhì)疏松的臨床療效確切,能夠顯著降低患者的血清AQP1、MMP-2、BALP及CTX-Ⅰ水平,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of alendronate sodium tablets combined with Alfacalcitol capsule in the treatment of peri-menopausal osteoporosis. Methods 56 patients with peri-menopausal osteoporosis were randomly divided into control group (n = 28) and experimental group (n = 2). 8 cases. The control group had 0.25 渭 g of Alfacalciol each time. QD, oral; The experimental group was treated with alendronate (70 mg / kg QD) on the basis of the treatment in the control group. The clinical efficacy of the two groups was compared. The level of matrix metalloproteinase 2 (MMP 2), bone alkaline phosphatase (BALP), type I collagen C terminal peptide (CTX- 鈪，

本文編號(hào)：1476267